Search
Now showing items 1-10 of 12
Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects
(Elsevier, 2022)
P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1α, miRNAs, and long noncoding (lnc)RNAs, ...
EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
(Elsevier, 2022)
Brain tumors are responsible for high mortality and morbidity worldwide. The brain tumor treatment depends on identification of molecular pathways involved in progression and malignancy. Enhancer of zeste homolog 2 (EZH2) ...
The long and short non-coding RNAs modulating EZH2 signaling in cancer
(2022)
Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in encoding proteins. However, they participate in developmental and biological processes and their abnormal expression affects cancer ...
Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity
(Wiley, 2022)
The identification of agents that can reverse drug resistance in cancer chemotherapy, andenhance the overall efficacy is of great interest. Paclitaxel (PTX) belongs to taxane family hat exerts an antitumor effect by ...
Targeted regulation of autophagy using nanoparticles: New insight into cancer therapy
(Elsevier, 2022)
Normal cells depend on autophagy to maintain cellular homeostasis by recycling damaged organelles and misfolded proteins and degrading toxic agents. Similar to apoptosis, targeting autophagy has been under attention in ...
Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance
(2022)
Introduction: The application of doxorubicin (DOX) in cancer therapy has been limited due to its drug resistance and poor internalization. Graphene oxide (GO) nanostructures have the capacity for DOX delivery while promoting ...
Long non-coding RNAs and exosomal incRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling
(Elsevier Science, 2022)
Among the different kinds of tumors threatening human life, lung cancer is one that is commonly observed in
both males and females. The aggressive behavior of lung cancer and interactions occurring in tumor microenvironment ...
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer (Journal of Hematology & Oncology, (2022), 15, 1, (18), 10.1186/s13045-022-01235-1)
(BioMed Central Ltd, 2022)
The original article [1] contained an error in co-author, Farid Hashemi’s name which has since been corrected. © 2022, The Author(s).
Targeting Nrf2 in ischemia-reperfusion alleviation: From signaling networks to therapeutic targeting
(Elsevier Inc., 2022)
The nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of redox balance and it responds to various cell stresses that oxidative stress is the most well-known one. The Nrf2 should undergo nuclear ...
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
(BioMed Central, 2022)
Cancer is one of the leading causes of death worldwide, and the factors responsible for its progression need to be elucidated. Exosomes are structures with an average size of 100 nm that can transport proteins, lipids, and ...
